atai Life Sciences launches InnarisBio, in partnership with the University of Queensland, with the aim to develop a more effective nose-to-brain delivery method for atai’s platform of mental health therapeutic programs
PsiloThera isn’t the only company changing the way we take drugs.
atai Life Sciences (ATAI) is partnering with the University of Queensland to commercialize a new nose-to-brain drug delivery technology for psychedelic and non-psychedelic compounds. The nasal method has potential to be more effective at treating central nervous system (CNS) disorders than oral administration because it bypasses the blood-brain barrier that can restrict the entry of therapeutic agents. The nose-to-brain technology may require a lower dose than oral methods and may reduce dosing frequency too – plus its non-invasive and painless.